Infant Bacterial Therapeutics Overview
- Year Founded
-
2011
- Status
-
Public
- Employees
-
10
- Stock Symbol
-
IBT B
- Share Price
-
$5.81
- (As of Friday Closing)
Infant Bacterial Therapeutics General Information
Description
Infant Bacterial Therapeutics AB is a pharmaceutical company. Its purpose is to develop and commercialize drugs for diseases affecting premature babies. Its focus is on the drug candidate IBP-9414, whose development program is designed to show a reduced incidence of necrotizing enterocolitis (NEC) and improved gastrointestinal function (SFT) when treated with IBP-9414's active substance Lactobacillus reuteri bacterial strain naturally found in human breast milk. Its portfolio also includes additional drug candidates, IBP-1016, IBP-1118 and IBP-1122. IBP1016, for the treatment of gastroschisis, is a life-threatening and rare disorder in which children are born with externalized gastrointestinal organs.
Contact Information
Website
www.ibtherapeutics.comCorporate Office
- Bryggargatan 10
- 111 21 Stockholm
- Sweden
Corporate Office
- Bryggargatan 10
- 111 21 Stockholm
- Sweden
Infant Bacterial Therapeutics Stock Performance
As of 16-May-2025, Infant Bacterial Therapeutics’s stock price is $5.81. Its current market cap is $77.6M with 13.5M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $5.81 | $5.76 | $2.11 - $12.61 | $77.6M | 13.5M | 20.2K | -$0.88 |
Infant Bacterial Therapeutics Financials Summary
As of 31-Mar-2025, Infant Bacterial Therapeutics has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 31-Mar-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 45,546 | 43,023 | 87,726 | 20,585 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (12,413) | (13,666) | (12,588) | (6,406) |
| Net Income | (11,812) | (12,945) | (11,578) | (6,452) |
| Total Assets | 20,765 | 21,713 | 35,155 | 33,515 |
| Total Debt | 0 | 0 | 0 | 0 |
Infant Bacterial Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Infant Bacterial Therapeutics Patents
Infant Bacterial Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202415791-D0 | Uses and methods | Pending | 25-Oct-2024 | ||
| CA-2972963-C | A method of activating lactic acid bacteria | Active | 14-Jan-2015 | ||
| CA-2972963-A1 | A method of activating lactic acid bacteria | Active | 14-Jan-2015 | ||
| AU-2016208007-B2 | A method of activating lactic acid bacteria | Active | 14-Jan-2015 | ||
| AU-2016208007-A1 | A method of activating lactic acid bacteria | Active | 14-Jan-2015 | A61K9/0053 |
Infant Bacterial Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Infant Bacterial Therapeutics ESG
Risk Overview
Risk Rating
Updated June, 01, 2023
33.27 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,631
Rank
Percentile
Pharmaceuticals
Industry
of 843
Rank
Percentile
Pharmaceuticals
Subindustry
of 419
Rank
Percentile
Infant Bacterial Therapeutics FAQs
-
When was Infant Bacterial Therapeutics founded?
Infant Bacterial Therapeutics was founded in 2011.
-
Where is Infant Bacterial Therapeutics headquartered?
Infant Bacterial Therapeutics is headquartered in Stockholm, Sweden.
-
What is the size of Infant Bacterial Therapeutics?
Infant Bacterial Therapeutics has 10 total employees.
-
What industry is Infant Bacterial Therapeutics in?
Infant Bacterial Therapeutics’s primary industry is Drug Discovery.
-
Is Infant Bacterial Therapeutics a private or public company?
Infant Bacterial Therapeutics is a Public company.
-
What is Infant Bacterial Therapeutics’s stock symbol?
The ticker symbol for Infant Bacterial Therapeutics is IBT B.
-
What is the current stock price of Infant Bacterial Therapeutics?
As of 16-May-2025 the stock price of Infant Bacterial Therapeutics is $5.81.
-
What is the current market cap of Infant Bacterial Therapeutics?
The current market capitalization of Infant Bacterial Therapeutics is $77.6M.
-
What is Infant Bacterial Therapeutics’s annual earnings per share (EPS)?
Infant Bacterial Therapeutics’s EPS for 12 months was -$0.88.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
